Results for Brain Tumors

Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.

Dr. Viaene's research interests include thalamocortical projections, CNS tumors, neurogenetic disorders, and hypoxic/ischemic brain injury.

Dr. Resnick's research focuses on the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. He studies signaling cascades and alterations to elucidate the molecular and genetic underpinnings in order to develop targeted therapies. As co-director of the Center of Data-Driven Discovery in Biomedicine, he leads a multidisciplinary team building and supporting a scalable, patient-focused healthcare and educational discovery ecosystem.

Dr. Minturn's primary clinical and research focus is the development of early-phase clinical trials targeting the molecular drivers of brain/spinal cord tumors. She also focuses on late effects of tumor-directed therapies on the developing nervous system and neurocognitive effects of treatment.

Dr. Storm directs CHOP's translational brain tumor laboratory and maintains a research program focusing on cell signaling cascades in pediatric brain tumors. The goal of this research is to understand and identify potential targets that can be developed into clinical therapy. His team is also leading collaborative efforts to de-silo research by engaging in open source platforms and cloud-based sharing.

Dr. Chen's research focuses on traumatic brain injury (TBI), multimodal neuromonitoring, and neurovascular disorders. She is interested in non-invasive forms of neuromonitoring thus leading to research efforts identifying reliable non-invasive methods for detecting intracranial hypertension in multiple disease processes including TBI and craniosynostosis.

Dr. Hocking’s research aims to better understand the neurodevelopmental consequences of having survived childhood cancer or having neurofibromatosis type 1, to identify those who are most at risk for poor outcomes, and to intervene in some way in order to improve quality of life.

Dr. Kennedy's current research focuses on epilepsy genetics and epilepsy surgery, including stereo-EEG, hemispherotomy, corpus callosotomy, and vagal nerve stimulation.

Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.

Dr. Wang works on biomarker identification using multiparametric magnetic resonance imaging and homo- and hetero-nuclear spectroscopy techniques for pediatric disease research including  tumors, iron overload, cystic fibrosis, muscular dystrophy, autism, mitochondrial, Gaucher’s, and Canavan’s diseases.